• Senior scientist, MRC Clinical Trials Unit at UCL, UCL
New research holds promise of a shorter treatment course for people with drugresistant- TB. Daniel Irungu/EPA

Drug‑resistant TB: a new study offers new hope

New research shows that the treatment of drug resistant-TB can be reduced from the current duration of 20 to 24 months to less than a year.

Contact Andrew for

  • General
  • Media request
  • Speaking request
  • Consulting / Advising
  • Research collaboration
  • Research supervision